齐拉西酮与奋乃静治疗急性精神分裂症对照研究

目的观察齐拉西酮治疗急性精神分裂症的临床疗效及安全性。方法将64例急性精神分裂症患者随机分为2组,各32例,研究组口服齐拉西酮,对照组口服奋乃静治疗,观察6周。于治疗前及治疗后第2周、4周、6周末采用阳性与阴性症状量表（positive and negative syndrome scale,PANSS）评定临床疗效,以副反应量表（TESS）评定不良反应。结果在第2周末评分研究组比对照组有显著下降,在第6周末2组评分均显著下降,差异无显著性;研究组不良反应发生率低于对照组,且程度较轻。结论齐拉西酮治疗急性精神分裂症起效快,疗效好,不良反应轻,安全性高。

A control study of ziprasidone and perphenazine in the treatment of acute schizophrenia

Objective To explore the efficacy and safety of ziprasidone and perphenazine in the treatment of acute schizophrenia. Methods Sixty-four acute schizophrenia patients were randomly assigned to two groups of 32 cases each,research group took orally ziprasidone and control group were given perphenazine for 6 weeks.Clinical efficacies were assessed with positive and negative syndrome scale（PANSS） and treatment emergent symptom scale（TESS） before treatment and at the end of the 2nd,4th and 6th week. Results The scores of PANSS in study group decreased significantly than control group in the second week.The difference was significant.The scores of PANSS in two groups were significantly decreased in the 6th week,the difference between two groups was not significant.The incidence of adverse reactions in study group was less than control group,and the extent was less. Conclusion Ziprasidone has rapid onset,curative effects,less adverse reaction and higher security in treatment of acute schizophrenia.